Cervical Cancer Research
Study Identifies Crucial Characteristic of High-Risk HPVPosted: October 5, 2017
By comparing the genomes of women infected with a high-risk type of human papillomavirus (HPV), researchers have found that a precise DNA sequence of a viral gene is associated with cervical cancer.
TCGA study identifies genomic features of cervical cancerPosted: January 23, 2017
Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in subclassification of the disease and may help target therapies that are most appropriate for each patient.
Gardasil 9 Vaccine Protects against Additional HPV TypesPosted: March 2, 2015
In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.
Multiple biopsies are superior to a single biopsy in detecting cervical cancer precursorsPosted: November 24, 2014
Performing multiple biopsies during a procedure known as colposcopy—visual inspection of the cervix—is more effective than performing only a single biopsy of the worst-appearing area for detecting cervical cancer precursors. This multiple biopsy approach may help to detect disease early and avoid repeated biopsies for women with initial negative findings, according to a new study by researchers at the National Cancer Institute and their colleagues.
NIH study finds negative HPV screening test result is a better predictor of low cervical cancer risk than a negative Pap testPosted: July 18, 2014
Based on a study that included more than 1 million women, investigators at NCI have determined that a negative test for HPV infection compared to a negative Pap test provides greater safety, or assurance, against future risk of cervical cancer.
NCI at ASCO: A brief overview on research in women's cancersPosted: June 2, 2014
The 2014 annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June highlighted results from a number of NCI-supported and -sponsored clinical trial results in women’s cancers. Taken together, these results represent important advances in our understanding of how to treat these diseases and improve the lives of those living with them.
Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancerUpdated: June 2, 2013
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an analysis of a large, randomized clinical trial.
Cervical Cancer: paradigms at home and abroadPosted: June 2, 2013
NCI funded a clinical trial that will have an impact on the treatment of late-stage cervical cancer, and also supported a screening trial in India using a network of community outreach workers offering low tech-screening by direct visualization of the cervix coated with dilute acetic acid (vinegar), a process known as VIA. Image depicts cervical cancer microvessel density which increases lethality of the cancer.
Treatment Regimen Extends Survival for Women with Cervical CancerUpdated: October 20, 2011
Patients with locally advanced cervical cancer who received gemcitabine (Gemzar®) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in Orlando.